

Gibson Dunn Represented Arrowhead Pharmaceuticals on Concurrent Public Offerings of Convertible Notes, Common Stock, and Pre-Funded Warrants and Related Capped Call Transactions

Firm News | January 12, 2026

Gibson Dunn represented Arrowhead Pharmaceuticals, Inc. on concurrent public offerings of convertible notes, common stock, and pre-funded warrants to purchase common stock for aggregate gross proceeds of \$930 million to Arrowhead and capped call transactions relating to the convertible notes. J.P. Morgan Securities and Jefferies acted as joint book-running managers for the notes offering and for the equity offering. BofA Securities, Piper Sandler, and RBC Capital Markets acted as joint bookrunners for both offerings. The Gibson Dunn capital markets team included partners Ryan Murr and Stewart McDowell and associates Lauren Navarro and Chad Kang. Partner Darius Mehraban and of counsel Adam Lapidus advised on derivatives matters. Partner Jin Hee Kim and associate Paul Rafla advised on finance matters. Partner Pamela Lawrence Endreny and associates Ryan Rott and Eytan de Gunzburg advised on tax matters.

Related People

[Ryan A. Murr](#)

[Stewart McDowell](#)

[Lauren Navarro](#)

[Chad Kang](#)

[Darius Mehraban](#)

[Adam Lapidus](#)

[Jin Hee Kim](#)

[Paul Rafla](#)

[Pamela Lawrence Endreny](#)

[Ryan Rott](#)

Related Capabilities

[Capital Markets](#)

[Life Sciences](#)

[Derivatives](#)

[Finance](#)

[Tax](#)